Xenon Pharmaceuticals (XENE)
NASDAQ:XENE
Want to see XENE full AI Analyst Report?
XENE Stock Chart & Stats
$59.70
-$0.78(-1.91%)
At close: 4:00 PM EST
$59.70
-$0.78(-1.91%)
Day’s Range― - ―
52-Week Range$30.00 - $63.95
Previous CloseN/A
Volume41.45K
Average Volume (3M)1.26M
Market Cap
$5.11B
Enterprise Value$3.66B
Total Cash (Recent Filing)$1.09B
Total Debt (Recent Filing)$7.49M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 12, 2026EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.70
Shares Outstanding96,665,550
10 Day Avg. Volume1,295,071
30 Day Avg. Volume1,263,681
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)6.11
Price to Sales (P/S)473.62
P/FCF Ratio-12.69
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-46.77
Enterprise Value/Ebitda-9.18
Forecast
1Y Price Target
$77.18Price Target Upside29.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.78
Revenue Forecast (FY)$2.19M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Multi-year RunwayA fortified cash position ($1.3B after a $747.5M financing) funds NDA preparation, manufacturing scale-up and commercial build for several years. This reduces near-term refinancing pressure and gives management time to execute regulatory and launch activities, materially lowering solvency risk.
Robust Phase 3 Efficacy And Durable Seizure Freedom SignalsClear, differentiated Phase 3 efficacy and strong long‑term OLE outcomes support a compelling clinical profile and potential label strength. Durable seizure‑freedom signals enhance prescriber adoption potential and payer value arguments, improving the odds of meaningful real‑world uptake if approved.
Broad, Precision‑medicine Pipeline With Strong HCP EngagementA diversified clinical portfolio (multiple Phase 3 and advancing Phase 1/2 programs) plus strong specialist endorsement reduces single‑asset binary risk and creates multiple commercialization opportunities. Precision‑medicine focus and HCP support strengthen scientific credibility and adoption prospects long term.
Bears Say
Pre‑commercial Profile With Sustained Cash BurnDespite a strong balance sheet, the company remains loss‑making with zero product revenue and substantial negative operating and free cash flow. Continued high burn elevates dilution risk or funding needs if regulatory or commercial timelines slip, pressuring long‑term shareholder returns until products generate revenue.
Commercial And Payer Execution Remains UnprovenTransitioning from R&D to commercialization requires scalable field teams, payer contracting and real‑world access strategies. Failure to obtain favorable formulary placement or to execute sales operations could blunt uptake and revenue despite positive clinical data, making launch execution a core long‑term risk.
Competitive Landscape And Cross‑trial UncertaintyEntrenched incumbents and differences between trials complicate positioning and payer negotiations. Real‑world dosing and competitor adoption patterns may reduce perceived differentiation, potentially slowing market penetration and exerting pricing/formulary pressure over the medium term.
Xenon News
XENE FAQ
What was Xenon Pharmaceuticals’s price range in the past 12 months?
Xenon Pharmaceuticals lowest stock price was $30.00 and its highest was $63.95 in the past 12 months.
What is Xenon Pharmaceuticals’s market cap?
Xenon Pharmaceuticals’s market cap is $5.11B.
When is Xenon Pharmaceuticals’s upcoming earnings report date?
Xenon Pharmaceuticals’s upcoming earnings report date is Aug 12, 2026 which is in 51 days.
How were Xenon Pharmaceuticals’s earnings last quarter?
Xenon Pharmaceuticals released its earnings results on May 07, 2026. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.179 by $0.009.
Is Xenon Pharmaceuticals overvalued?
According to Wall Street analysts Xenon Pharmaceuticals’s price is currently Undervalued.
Does Xenon Pharmaceuticals pay dividends?
Xenon Pharmaceuticals does not currently pay dividends.
What is Xenon Pharmaceuticals’s EPS estimate?
Xenon Pharmaceuticals’s EPS estimate is -1.14.
How many shares outstanding does Xenon Pharmaceuticals have?
Xenon Pharmaceuticals has 96,665,550 shares outstanding.
What happened to Xenon Pharmaceuticals’s price movement after its last earnings report?
Xenon Pharmaceuticals reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.179. Following the earnings report the stock price went up 0.786%.
Which hedge fund is a major shareholder of Xenon Pharmaceuticals?
Currently, no hedge funds are holding shares in XENE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.18 (29.29% Upside)
$77.18 (29.29% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 8.7%
Last 30 Days ▲ 8.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.86%
12-Months-Change
Fundamentals
Return on Equity
-49.23%
Trailing 12-Months
Asset Growth
86.58%
Trailing 12-Months
Company Description
Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
XENE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed overwhelmingly positive clinical and corporate momentum: a highly favorable XTOL-2 Phase 3 data set with strong efficacy, long-term seizure freedom signals, a consistent safety profile, and a fortified balance sheet ($1.3B) supporting operations into 2029. The company has a clear regulatory path (NDA guidance for 2026) and active commercial and payer engagement. Remaining uncertainties are largely execution and timing risks (regulatory scheduling, commercial launch logistics, payer access) and limited near-term public granularity on Phase 1 pain data. On balance, the highlights are substantial and materially outweigh the modest operational and timing risks discussed.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$77.18
▲(29.29% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Scholar Rock Holding
―
Immunovant
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
0.13% Insiders
28.94% Mutual Funds
51.33% Other Institutional Investors
13.83% Public Companies and
Individual Investors